

First quarter 2026 earnings presentation

May 7, 2026



Definitive Healthcare

Cautionary statement regarding forward-looking statements

This presentation includes forward-looking statements that reflect our current views with respect to future events and financial performance. Such statements are provided under the “safe harbor” protection of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by words or phrases written in the future tense and/or preceded by words such as “should,” “may,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “would,” “potentially,” “will,” “continues,” “assumes,” or similar words or variations thereof, or the negative thereof, references to future periods, or by the inclusion of forecasts or projections, but these terms are not the exclusive means of identifying such statements. Examples of forward-looking statements include, but are not limited to, statements we make regarding our outlook, financial guidance, the benefits of our differentiated data and healthcare commercial intelligence solutions, our overall future prospects and growth opportunities, customer behaviors and use of our solutions, generating value for our customers and shareholders, the market, industry and macroeconomic environment, our planned investments and operational strategy, our plans to improve our operational and financial performance, our business, our market opportunity, and customer growth.

Forward-looking statements in this presentation are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the following: our inability to achieve the anticipated cost savings, operating efficiencies or other benefits of our internal restructuring activities, global geopolitical tension and difficult macroeconomic conditions; actual or potential changes in international, national, regional and local economic, business and financial conditions, including tariffs, sanctions, trade barriers, recessions, fluctuating inflation, high interest rates, volatility in the capital markets and related market uncertainty; the impact of difficult macroeconomic conditions on our new and existing customers; our inability to acquire new customers and generate additional revenue from existing customers; our inability to generate sales of subscriptions to our platform or any decline in demand for our platform and the data we offer; the competitiveness of the market in which we operate and our ability to compete effectively; the failure to maintain and improve our platform, or develop new modules or insights for healthcare commercial intelligence; the inability to obtain and maintain accurate, comprehensive or reliable data, which could result in reduced demand for our platform; the risk that our recent growth rates may not be indicative of our future growth; the inability to achieve or sustain GAAP or non-GAAP profitability in the future as we increase investments in our business; the loss of our access to our data providers; the failure to respond to advances in healthcare commercial intelligence; an inability to attract new customers and expand subscriptions of current customers; our ability to successfully transition executive leadership, the risk of cyber-attacks and security vulnerabilities; litigation, investigations or other legal, governmental or regulatory actions; the possibility that our security measures are breached or unauthorized access to data is otherwise obtained; the risk that additional material weaknesses or significant deficiencies that will occur in the future; and the risks of being required to collect sales or other related taxes for subscriptions to our platform in jurisdictions where we have not historically done so.

Additional factors or events that could cause our actual performance to differ from these forward-looking statements may emerge from time to time, and it is not possible for us to predict all of them. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual financial condition, results of operations, future performance and business may vary in material respects from the performance projected in these forward-looking statements.

For additional discussion of factors that could impact our operational and financial results, refer to our annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q, which are or will be available on the Investor Relations page of our website at ir.definitivehc.com and on the SEC website at www.sec.gov.

All information in this presentation speaks only as of March 31, 2026, unless otherwise indicated. We undertake no obligation to publicly update this information, whether as a result of new information, future developments or otherwise, except as may be required by law.

Non-GAAP Financial Measures

The historical financial information in this presentation includes information that is not presented in accordance with generally accepted accounting principles in the United States (“GAAP”), such as Adjusted EBITDA, Adjusted Gross Profit, Adjusted Gross Margin, non-GAAP Sales and Marketing expense, non-GAAP Product Development expense, non-GAAP General and Administrative expense, Adjusted EBITDA Margin, Adjusted Operating Income, Adjusted Net Income, Adjusted Net Income Per Diluted Share, Unlevered Free Cash Flow and Unlevered Free Cash Flow Margin. These are supplemental financial measures of our performance and should not be considered substitutes for net (loss) income, gross profit or any other measure derived in accordance with GAAP. Non-GAAP measures in this presentation may be calculated in ways that are not comparable to similarly titled measures reported by other companies. Our presentation of these non-GAAP financial measures are intended as supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. We believe that these supplemental non-GAAP financial measures are useful to investors because they allow for an evaluation of the Company with a focus on the performance of its core operations, including providing meaningful comparisons of financial results to historical periods and to the financial results of peer and competitor companies.

We do not provide a quantitative reconciliation of the forward-looking non-GAAP financial measures included in this presentation to the most directly comparable GAAP measures due to the high variability and difficulty to predict certain items excluded from these non-GAAP financial measures; in particular, the effects of stock-based compensation expense, taxes and amounts under the exchange tax receivable agreement, deferred tax assets and deferred tax liabilities, goodwill impairments and restructuring, integration and transaction expenses. We expect the variability of these excluded items may have a significant, and potentially unpredictable, impact on our future GAAP financial results. In evaluating our non-GAAP financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in these presentations. See the Appendix to this presentation for a reconciliation of each non-GAAP financial measure to its most directly comparable financial measure stated in accordance with GAAP.

References in this presentation to profitability are on an Adjusted EBITDA basis.



Q1'26



Q1 2026 performance highlights



“Definitive Healthcare started 2026 on a solid note, with financial results at or above the high end of our guidance ranges. We continue to make progress against each of our strategic pillars and are realizing some positive early indications of success, including improvements in retention rates. We remain confident we are making the right investments to drive sustained long-term operational and financial improvements, while also continuing to generate significant profitability and cash flow.”

— **Kevin Coop**, Chief Executive Officer



“While we are navigating ongoing top-line pressures, we remain focused on sustaining non-GAAP profitability and a strong margin profile. And we will continue to invest thoughtfully to support a return to growth. Our first quarter results and full year guidance reflect the progress we are making and this commitment.”

— **Casey Heller**, Chief Financial Officer

(6%)
Revenue Decline YoY

27%
aEBITDA margin

\$49.9 million
TTM uFCF



Q1 performance and guidance

\$ Millions, except percentages and per share info	Q1'26	Guidance Range
Revenue	\$55.9	\$54.0 - \$56.0
<i>% growth YoY</i>	<i>(6%)</i>	<i>(9%) - (5%)</i>
Adjusted Operating Income ¹	\$12.9	\$9.5 - \$10.5
<i>% of revenue</i>	<i>23%</i>	<i>17 - 19%</i>
Adjusted EBITDA ¹	\$15.3	\$12.0 – \$13.0
<i>% of revenue</i>	<i>27%</i>	<i>22 - 23%</i>
Adjusted Net Income ¹	\$8.5	\$4.0 – \$5.0
Adjusted EPS ¹	\$0.06	\$0.03

- Q1 results were at or above the high end of the guided range.
- Q1 non-GAAP profit exceeded expectations and delivered margin expansion across Adjusted Gross Margin, Adjusted Operating Income and Adjusted EBITDA.



¹ Non-GAAP measure. See Appendix for a reconciliation of the non-GAAP measure to the most directly comparable financial measure stated in accordance with GAAP.


Q1 2026 results

P&L on non-GAAP basis

- Q1 performance at or above high end of guided ranges
- Adjusted EBITDA margin improvement YoY driven by broader expense efficiency, higher capitalized software spend and a timing gap of a new data source

\$ Millions except per share amounts	Q1'26	Q1'25	YoY Change
Total Revenue	\$55.9	\$59.2	(6%)
Adjusted Gross Profit	\$45.2	\$47.1	(4%)
Adjusted Gross Profit margin	81%	80%	130 bps
Non-GAAP Sales & Marketing	18.6	19.5	(4%)
Non-GAAP Product Development	6.1	7.4	(17%)
Non-GAAP General and Administrative	6.6	7.6	(14%)
Total Non-GAAP Expense	\$31.3	\$34.5	(9%)
Adjusted Operating Income	12.9	12.0	8%
Adjusted Operating Income margin	23%	20%	280 bps
Adjusted EBITDA	15.3	14.7	4%
Adjusted EBITDA margin	27%	25%	260 bps
Adjusted Net Income	8.5	7.0	22%
Adjusted EPS	\$0.06	\$0.05	30%

Revenue mix



4% YoY

aEBITDA improvement

\$15.3M aEBITDA in Q1'26

27%

aEBITDA margin

260 bps aEBITDA margin improvement YoY



Q1 2026 cash flow and balance sheet highlights

\$ Millions	Q1'26	Q1'25	YoY Change
Cash Flow from Operations	\$11.6	\$26.1	(56%)
Unlevered Free Cash Flow ¹	\$18.0	\$22.9	(22%)
\$49.9 million TTM uFCF⁵			
\$ Millions	Q1'26	Q1'25	YoY Change
Cash, cash equivalents & short-term investments ²	\$178.1	\$200.7	(11%)
Total debt outstanding ³	\$164.1	\$172.8	(5%)
Net leverage ratio ⁴	<0x	<0x	
70% TTM conversion of aEBITDA to uFCF⁵			
Current remaining performance obligations	\$160.5	\$181.7	(12%)
Total remaining performance obligations	\$230.5	\$281.6	(18%)
Deferred revenue	\$99.2	\$112.5	(12%)

**\$49.9 million
TTM uFCF⁵**

**70%
TTM conversion of
aEBITDA to uFCF⁵**

¹ Non-GAAP measure. See Appendix for a reconciliation of the non-GAAP measure to the most directly comparable financial measure stated in accordance with GAAP.

² Total cash and investments was comprised of \$157.6 million in cash and cash equivalents and \$20.4 million of short-term investments.

³ As of March,31, 2026, the Company's all-in floating interest rate on \$164.1 million of outstanding debt is 3.7% SOFR + 2.1% margin = 5.8%. 80% of outstanding principal is protected by 4.5% SOFR interest rate caps.

⁴ The net leverage ratio is defined as total outstanding debt less cash and short-term investments divided by TTM Adjusted EBITDA.

⁵ As of March,31 2026.



Guidance



Q2 and FY 2026 guidance

As of May 7, 2026

\$ MILLIONS, except percentages and per share info	Second Quarter 2026	Full Year 2026
Revenue	\$55.0 - \$56.0	\$220.0 - \$226.0
<i>% change YoY</i>	<i>(9%) - (8%)</i>	<i>(9%) - (6%)</i>
Adjusted Operating Income ¹	\$10.5 - \$11.5	\$43.5 - \$47.5
<i>% of revenue</i>	<i>19 - 21%</i>	<i>20 - 21%</i>
Adjusted EBITDA ¹	\$13.5 - \$14.5	\$55.0 - \$59.0
<i>% of revenue</i>	<i>24 - 26%</i>	<i>25 - 26%</i>
Adjusted Net Income ¹	\$5.0 - \$6.0	\$23.0 - \$27.0
Adjusted EPS ¹	\$0.03 - \$0.04 ²	\$0.16 - \$0.19 ³

- We are maintaining our full year revenue guide, which reflects our view of the year under existing macroeconomic conditions.
- The solid performance in the first quarter combined with our expectations for the remainder gives us the confidence to further improve our full year guide on profit.
- The adjusted EBITDA mid-point guide was increased by \$1.5 million reflecting our ongoing commitment to maintaining strong margins while investing in our key growth areas.

¹ Non-GAAP measure. We do not provide a quantitative reconciliation of the forward-looking non-GAAP financial measures to the most directly comparable GAAP measures due to the high variability and difficulty to predict certain items excluded from these non-GAAP financial measures; in particular, the effects of equity-based compensation expense, taxes and amounts under the tax receivable agreement, deferred tax assets and deferred tax liabilities, and transaction, integration, and restructuring expenses. We expect the variability of these excluded items may have a significant, and potentially unpredictable, impact on our future GAAP financial results.

² Based on approximately 144.2 million weighted-average diluted shares outstanding.

³ Based on approximately 144.9 million weighted-average diluted shares outstanding.



Appendix

Non-GAAP reconciliations & basis of presentation



Key shareholder statistics

<u>Key shareholder statistics as of 3/31/2026</u>	<u>Public Shares (Class A)</u>	<u>Minority Interest (Class B)</u>	<u>Combined</u>
Sponsor ownership (as-if converted) ¹	63,935,333	13,843,158	77,778,491
Management, Directors & employees	283,640	24,382,175	24,665,815
Float	41,044,475		41,044,475
Vested (as-if converted)	105,263,448	38,225,333	143,488,781
% Controlling vs NCI	73.4%	26.6%	100%
<i>Float as %</i>	39.0%		28.6%
<i>Management, Directors & employees</i>	0.3%	63.8%	17.2%
<i>Sponsor ownership (as-if converted)</i>	60.7%	36.2%	54.2%
	100.0%	100.0%	100.0%

Comments

- 114K Class B shares were exchanged into Class A public shares in the quarter
- 1.1M Class A shares issued from RSU vesting in the quarter
- Minority interest as of March 31, 2026 decreased to 26.6% from 26.9% at December 31, 2025
- Effective non-GAAP tax rate is 19.0%, compared to 18.9% at December 31, 2025 (73.1% vested Pubco shares x 26% tax rate) ²
- As of March 31, 2026, there were 22.6 million unvested Class A RSUs. All Class B MIUs have vested

¹ Sponsor ownership consists of Advent and Spectrum Equity. In an 8-K filing on November 1, 2024, in conjunction with the expanded share repurchase program, a voting agreement with Advent was established. Advent is required to vote all shares of voting stock of the Company, beneficially owned by Advent that exceed 40.3% of the outstanding Voting Securities of the Company as a result of the Repurchase Program, in the same proportion as all votes cast by stockholders other than Advent.

² Non-GAAP tax rate is based on prior quarter-end controlling interest % applied to the statutory tax rate.



Reconciliation from GAAP gross profit and margin to adjusted gross profit and margin

THREE MONTHS ENDED MARCH 31,

\$ THOUSANDS	2026	2025	\$	%
GAAP Gross Profit	\$41,650	\$43,760	(\$2,110)	(5%)
Amortization of intangible assets resulting from acquisition-related purchase accounting adjustments	3,487	3,153	334	11%
Equity-based compensation	82	160	(78)	(49%)
Adjusted Gross Profit	\$45,219	\$47,073	(\$1,854)	(4%)
GAAP Gross Profit Margin	74%	74%		
Amortization of intangible assets resulting from acquisition-related purchase accounting adjustments	6%	5%		
Equity-based compensation	0%	0%		
Adjusted Gross Profit Margin	81%	80%		
Revenue	55,929	59,191	(3,262)	(6%)



Reconciliation from GAAP to non-GAAP operating expenses

\$ THOUSANDS	THREE MONTHS ENDED MARCH 31,			
	2026	2025	\$	%
GAAP Sales & Marketing	\$19,578	\$20,653	(\$1,075)	(5%)
Equity-based compensation	(951)	(1,179)	\$228	(19%)
Other non-core items ¹	(16)	-	(\$16)	(100%)
Non-GAAP Sales & Marketing	\$18,611	\$19,474	(\$863)	(4%)
GAAP Product Development	\$6,499	\$9,301	(\$2,802)	(30%)
Equity-based compensation	(375)	(1,739)	\$1,364	(78%)
Other non-core items ¹	(9)	(168)	\$159	(94%)
Non-GAAP Product Development	\$6,115	\$7,394	(\$1,280)	(17%)
GAAP General & Administrative	\$12,084	\$12,269	(\$185)	(2%)
Equity-based compensation	(3,812)	(4,242)	\$430	(10%)
Other non-core items ¹	(1,668)	(392)	(\$1,276)	>100%
Non-GAAP General & Administrative	\$6,604	\$7,635	(\$1,031)	(14%)

¹ Other non-core items represent expenses driven by events that are typically by nature one-time, non-operational and/or unrelated to our core operations. These expenses are comprised of non-core legal, regulatory and advisory costs isolated to unique and extraordinary litigation, legal, regulatory, and other matters that are not considered normal and recurring business activity, including professional fees in connection with the evaluation of strategic, financial, tax, and capital structure alternatives. Other non-core items also include consulting fees and severance costs associated with strategic transition initiatives, as well as other non-core items.



Reconciliation from net loss to adjusted operating income and adjusted net income

\$ THOUSANDS	THREE MONTHS ENDED MARCH 31,			
	2026	2025	\$	%
GAAP Net loss	(\$192,354)	(\$155,093)	(\$37,261)	24%
Interest expense, net	1,332	381	951	>100%
Income tax benefit	(3,435)	(10,886)	7,451	(68%)
Loss on partial extinguishment of debt	-	507	(507)	(100%)
Other income, net	(6,833)	(19,695)	12,862	(65%)
GAAP Operating loss	(\$201,290)	(\$184,786)	(\$16,504)	9%
Transaction, integration, and restructuring expenses	(765)	1,265	(2,030)	>(100%)
Equity-based compensation	5,220	7,319	(2,099)	(29%)
Goodwill impairment	197,219	176,531	20,688	12%
Other non-core items	1,693	560	1,133	>100%
Amortization of intangible assets acquired through business combinations	10,808	11,089	(281)	(3%)
Adjusted Operating Income	\$12,885	\$11,978	\$907	8%
Interest expense, net	(1,332)	(381)	(951)	>(100%)
Recurring income tax (provision) benefit	(127)	352	(479)	>(100%)
Foreign currency gain (loss)	312	(969)	1,281	>100%
Tax impacts of adjustments to net loss	(3,221)	(4,008)	787	(20%)
Adjusted Net Income	\$8,517	\$6,972	\$1,545	22%



Reconciliation from net loss to adjusted EBITDA

\$ THOUSANDS	THREE MONTHS ENDED MARCH 31,			
	2026	2025	\$	%
GAAP Net loss	(\$192,354)	(\$155,093)	(\$37,261)	24%
Interest expense, net	1,332	381	951	>100%
Income tax benefit	(3,435)	(10,886)	7,451	(68%)
Loss on partial extinguishment of debt	-	507	(507)	(100%)
Depreciation & amortization	13,249	13,817	(568)	(4%)
Transaction, integration and restructuring expenses	(765)	1,265	(2,030)	>(100%)
Goodwill impairment	197,219	176,531	20,688	12%
Equity-based compensation	5,220	7,319	(2,099)	(29%)
Other income, net	(6,833)	(19,695)	12,862	(65%)
Other non-core items	1,693	560	1,133	>100%
Adjusted EBITDA	\$15,326	\$14,706	\$620	4%
Revenue	55,929	59,191	(3,262)	(6%)
Adjusted EBITDA margin	27%	25%		



Reconciliation from cash flow from operations to unlevered free cash flow

\$ THOUSANDS	THREE MONTHS ENDED MARCH 31,			
	2026	2025	\$	%
Cash Flow from Operations	\$11,564	\$26,066	(\$14,502)	(56%)
Cash interest expense	2,472	2,242	\$230	10%
Transaction, integration, and restructuring expenses paid in cash ¹	4,116	1,763	\$2,353	>100%
Other non-core Items paid in cash ¹	3,010	560	\$2,450	>100%
Purchases of property, equipment and other assets	(3,202)	(7,706)	\$4,504	(58%)
Unlevered Free Cash Flow	\$17,960	\$22,925	(\$4,965)	(22%)
Revenue	55,929	59,191	(3,262)	(6%)
Unlevered Free Cash Flow Margin	32%	39%		

¹ Transaction and integration expenses paid in cash primarily represent legal, accounting, and consulting expenses related to our acquisitions and strategic partnerships; restructuring expenses paid in cash relate to our restructuring plan announced in the first quarter of 2026; non-core items paid in cash represent expenses driven by events that are typically one-time, non-operational in nature, and/or unrelated to our core operations.



Schedule of transaction, integration and restructuring expense and other non-core items

\$ THOUSANDS	THREE MONTHS ENDED MARCH 31,	
	2026	2025
Merger and acquisition due diligence and transaction costs	\$352	\$1,178
Integration costs	(2,169)	557
Fair value adjustment for contingent consideration	-	(690)
Restructuring charges for severance and other separation costs	1,052	28
Office closure and relocation restructuring charges and impairments	-	192
Total transaction, integration and restructuring expense	(\$765)	\$1,265

\$ THOUSANDS	THREE MONTHS ENDED MARCH 31,	
	2026	2025
Non-core legal, regulatory, and advisory	\$1,676	\$53
Consulting and severance costs for strategic transition initiatives	-	168
Other non-core expenses	17	339
Total other non-core items	\$1,693	\$560



Non-GAAP financial measures / Basis of presentation

Enterprise Customers: Customers generating more than \$100,000 in ARR (as the term is defined below).

Annual Recurring Revenue (ARR): Refers to annual recurring revenue as of period end, which is calculated by aggregating annual subscription revenue from committed contractual amounts for all existing customers during that period. ARR may also include, in rare circumstances, existing customers with expired contracts who have provided oral or written commitments to renew.

Net Dollar Retention Rate (NDR): Refers to net dollar retention rate, which we calculate as the percentage of ARR retained from existing customers across a defined period, after accounting for upsell, down-sell, pricing changes and churn. We calculate net dollar retention as beginning ARR for a period, plus (i) expansion ARR (including, but not limited to, upsell and pricing increases), less (ii) churn (including, but not limited to, non-renewals and contractions), divided by (iii) beginning ARR for a period.

Revenue: GAAP revenue.

Organic revenue growth: is calculated as performance as if we had owned an acquired business in the same period a year ago.

Adjusted Gross Profit: is calculated as revenue less cost of revenue (excluding acquisition-related depreciation and amortization) and equity based compensation.

Gross Profit: is revenue less cost of revenue.

Gross Margin: is calculated as Gross Profit divided by GAAP Revenue.

Adjusted Gross Margin: is calculated as Adjusted Gross Profit divided by GAAP Revenue.

Non-GAAP Sales and Marketing: is calculated as GAAP Sales and Marketing expense less equity-compensation costs and non-core & one-time items allocated to Sales and Marketing.

Non-GAAP Product Development: is calculated as GAAP Product Development expense less equity-compensation costs and non-core & one-time items allocated to Product Development.

Non-GAAP General & Administrative: is calculated as GAAP General & Administrative expense less equity-compensation costs and non-core & one-time items allocated to General & Administrative.

cRPO: Represents the amount of contracted future revenue that has not yet been recognized, including both deferred revenue and non-cancelable contracted amounts that will be invoiced and recognized as revenue within the next twelve months. cRPO is not necessarily indicative of future revenue growth.

RPO: Represents the amount of contracted future revenue that has not yet been recognized, including both deferred revenue and non-cancelable contracted amounts that will be invoiced and recognized in the future. RPO is not necessarily indicative of future revenue growth.

Goodwill Impairment: Represents a non-cash, pretax, impairment charge of goodwill due to a decline in market capitalization in which the fair value of our single reporting unit was lower than its carrying value.

EBITDA: Defined as earnings before debt-related costs, including interest expense (income), net and loss from partial extinguishment of debt, income taxes and depreciation and amortization.

Adjusted EBITDA: Defined as EBITDA adjusted to exclude certain items of a significant or unusual nature, including other income and expense, equity-based compensation, goodwill impairments, transaction, integration and restructuring expenses and other non-core expenses.

Adjusted EBITDA Margin: defined as Adjusted EBITDA divided by GAAP Revenue.

Adjusted Operating Income: defined as GAAP loss from operations plus acquisition-related amortization, equity-based compensation, goodwill impairments, transaction, integration, and restructuring expenses and other non-core expenses.

Adjusted Net Income: defined as Adjusted Operating Income less interest expense, net recurring income tax benefit, foreign currency (loss) gain, and tax effects of adjustments to arrive at Adjusted Operating Income.

Adjusted EPS: defined as Adjusted Net Income divided by weighted-average diluted shares outstanding.

Unlevered Free Cash Flow (uFCF): Defined as net cash provided by (used in) operating activities less purchases of property, equipment and data assets, plus cash interest expense and cash payments related to transaction, integration and restructuring related expenses, earnouts and other non-core items paid in cash. Unlevered Free Cash Flow does not represent residual cash flow available for discretionary expenditures since, among other things, we have mandatory debt service requirements.

Unlevered Free Cash Flow Margin: Calculated as Unlevered Free Cash Flow divided by GAAP Revenue.

Financial Audits: Core metrics and historical financials shown throughout the presentation should be considered unaudited.

Rounding: In some instances, rounding has occurred throughout the presentation.

Our use of these non-GAAP terms may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies and are not measures of performance calculated in accordance with GAAP. Our presentation of these non-GAAP financial measures are intended as supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. These non-GAAP financial measures should not be considered as alternatives to net cash provided by (used in) operating activities, net cash provided by (used in) operating activities margin, (loss) income from operations, net (loss) income, net (loss) income margin, gross profit, gross margin, earnings per share or any other performance measures derived in accordance with GAAP, or as measures of operating cash flows or liquidity. In evaluating our non-GAAP financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in these presentations.

